Document is current
Any future updates will be listed below
-
Authors
Pahnke, Simon https://orcid.org/0000-0002-3541-2027
Abalo, Kossi D.
Ekberg, Sara
Albertsson-Lindblad, Alexandra
E. Smedby, Karin
Jerkeman, Mats https://orcid.org/0000-0003-4509-6707
Glimelius, Ingrid https://orcid.org/0000-0001-6158-3041
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2022-00801)
Cancerfonden (222167Pj)
- License Information
-
More Information
Article History
Received: 2 May 2024
Revised: 18 November 2024
Accepted: 6 December 2024
First Online: 19 December 2024
Competing interests
: Mats Jerkeman received honoraria from Abbvie, AstraZeneca, BMS, Kite/Gilead, Pierre Fabre, Roche, Sobi and Takeda, and research support from Abbvie, AstraZeneca, BMS and Roche. Ingrid Glimelius received research support from Takeda and participated in educational sessions arranged by Jansen Cilag and Abbvie. Karin E Smedby received honoraria from Incyte and Celgene, and research support from Janssen Cilag. The other authors have no relevant financial or non-financial interests to disclose.
: The study was approved by the Regional Board of the Ethical Committee in Stockholm, Sweden (2007/1335-31/4, 2010/1624-32), Lund (2012/212), and Uppsala (2016/178), and performed in accordance with relevant guidelines and regulations. Patient data is registered in the Swedish Lymphoma Register as part of routine healthcare quality control programs, with an opt-out possibility for those not willing to participate. As detailed in the ethical approval, linkage of the Swedish Lymphoma Register to other registries is performed at the registry-keeping authority without written informed consent, and only pseudonymized data have been accessible to/and analysed by the research group.
